Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$4.99 -3.1%	$5.35	$1.67 ▼ $7.29	$504.63M	0.94	6.12 million shs	3.76 million shs
PGEN Precigen	$1.85 -3.1%	$1.65	$0.65 ▼ $2.17	$569.13M	1.87	3.15 million shs	3.36 million shs
SIGA Siga Technologies	$8.58 -2.3%	$6.91	$4.95 ▼ $11.91	$628.70M	0.94	581,263 shs	507,609 shs
UPXI Upexi	$7.90 +0.9%	$6.60	$1.90 ▼ $22.57	$699.70M	-0.52	12.90 million shs	10.58 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	-3.11%	-4.77%	-11.37%	+52.60%	+169.73%
PGEN Precigen	-3.14%	-1.60%	0.00%	+27.59%	+65.18%
SIGA Siga Technologies	-2.28%	+0.35%	+28.06%	+43.24%	-28.32%
UPXI Upexi	+0.89%	+41.83%	+51.92%	-22.47%	+94.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.2023 of 5 stars	3.6	1.0	0.0	2.2	1.7	0.6
PGEN Precigen	4.0573 of 5 stars	3.5	0.0	4.7	3.8	1.7	0.6
SIGA Siga Technologies	2.0791 of 5 stars	0.0	2.0	0.0	2.5	0.8	3.1
UPXI Upexi	3.0083 of 5 stars	3.8	2.0	0.0	3.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.17	Buy	$21.25	325.85% Upside
PGEN Precigen	3.00	Buy	$6.00	224.32% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
UPXI Upexi	3.50	Strong Buy	$15.50	96.20% Upside

Current Analyst Ratings Breakdown

Latest UPXI, PGEN, SIGA, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
8/13/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/4/2025	UPXI Upexi	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,125.96	N/A	N/A	$0.76 per share	6.57
PGEN Precigen	$3.92M	140.62	N/A	N/A	($0.12) per share	-15.42
SIGA Siga Technologies	$138.72M	4.43	$0.82 per share	10.49	$2.92 per share	2.94
UPXI Upexi	$26M	27.15	N/A	N/A	$6.24 per share	1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.80	N/A	N/A	N/A	N/A	-93.69%	-68.83%	N/A
PGEN Precigen	-$126.24M	-$0.42	N/A	N/A	N/A	-2,868.66%	-842.83%	-78.98%	N/A
SIGA Siga Technologies	$59.21M	$1.13	7.59	6.86	N/A	45.73%	40.52%	35.62%	N/A
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest UPXI, PGEN, SIGA, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PGEN Precigen	-$0.14	-$0.11	+$0.03	-$0.09	$0.67 million	$0.86 million
8/7/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	-$0.22	-$0.04	-$0.22	N/A	N/A
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	5.63	5.63
PGEN Precigen	N/A	2.71	3.53
SIGA Siga Technologies	N/A	10.09	8.52
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
PGEN Precigen	33.51%
SIGA Siga Technologies	55.40%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
PGEN Precigen	47.10%
SIGA Siga Technologies	1.95%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	97.99 million	94.36 million	Optionable
PGEN Precigen	190	297.97 million	156.15 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable
UPXI Upexi	130	89.36 million	61.12 million	Optionable

UPXI, PGEN, SIGA, and ATYR Headlines

Recent News About These Companies

Upexi establishes Advisory Committee, welcomes Hayes as first member

August 13 at 3:39 AM | msn.com

Former Amazon aggregator turns to Solana, records $70K in daily rewards

August 13 at 3:39 AM | msn.com

Upexi (NASDAQ:UPXI) Sees Unusually-High Trading Volume - Time to Buy?

August 12 at 3:43 PM | marketbeat.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)

August 11, 2025 | prnewswire.com

Upexi (NASDAQ:UPXI) Shares Up 14.2% - Here's What Happened

August 9, 2025 | marketbeat.com

Crypto Currents: SEC eases staking rules as bitcoin miners pivot to AI

August 6, 2025 | msn.com

Alliance Global Partners Begins Coverage on Upexi (NASDAQ:UPXI)

August 6, 2025 | americanbankingnews.com

Upexi Surpasses 2 Million SOL in its Treasury

August 5, 2025 | taiwannews.com.twT

Solana Treasury Company Upexi Surpasses 2M in SOL Holdings

August 5, 2025 | coindesk.com

Upexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global Partners

August 5, 2025 | marketbeat.com

Upexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 Shares

July 31, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of Stock

July 31, 2025 | insidertrades.com

Upexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?

July 31, 2025 | marketbeat.com

Upexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14th

July 30, 2025 | manilatimes.netM

Upexi Secures $500M Equity Deal to Buy More Solana Despite Stock Drop

July 30, 2025 | thecurrencyanalytics.comT

Upexi enters $500M equity line agreement

July 29, 2025 | msn.com

Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy

July 29, 2025 | manilatimes.netM

Solana Treasury firm Upexi secures $500M to acquire more SOL

July 29, 2025 | msn.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Here's Why

July 28, 2025 | marketbeat.com

Traders Buy Large Volume of Call Options on Upexi (NASDAQ:UPXI)

July 28, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, PGEN, SIGA, and ATYR Company Descriptions

aTyr Pharma NASDAQ:ATYR

$4.99 -0.16 (-3.11%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$5.07 +0.08 (+1.50%)

As of 04:18 AM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Precigen NASDAQ:PGEN

$1.85 -0.06 (-3.14%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.45 +0.60 (+32.65%)

As of 08/14/2025 06:30 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Siga Technologies NASDAQ:SIGA

$8.58 -0.20 (-2.28%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$8.58 0.00 (0.00%)

As of 04:05 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Upexi NASDAQ:UPXI

$7.90 +0.07 (+0.89%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.84 -0.06 (-0.76%)

As of 04:25 AM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time